By John Harbison|2017-02-20T06:55:03-08:00December 13, 2016|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer’s disease
